TY - JOUR
T1 - Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion
AU - Giroux, Nicholas S.
AU - Ding, Shengli
AU - McClain, Micah T.
AU - Burke, Thomas W.
AU - Petzold, Elizabeth
AU - Chung, Hong A.
AU - Rivera, Grecia O.
AU - Wang, Ergang
AU - Xi, Rui
AU - Bose, Shree
AU - Rotstein, Tomer
AU - Nicholson, Bradly P.
AU - Chen, Tianyi
AU - Henao, Ricardo
AU - Sempowski, Gregory D.
AU - Denny, Thomas N.
AU - De Ussel, Maria Iglesias
AU - Satterwhite, Lisa L.
AU - Ko, Emily R.
AU - Ginsburg, Geoffrey S.
AU - Kraft, Bryan D.
AU - Tsalik, Ephraim L.
AU - Shen, Xiling
AU - Woods, Christopher W.
N1 - Funding Information:
This work was supported by the U.S. Defense Advanced Projects Agency (DARPA, N66001-09-C-2082 and HR0011-17-2-0069) to XS and CWW, the Veterans Affairs Health System and Virology Quality Assurance (VQA) 75N93019C00015 to CWW, NIH/NHLBI K08HL130557 to BDK, DARPA/USMRAA W911NF1920111 to XS, NIH/NIGMS R35GM122465 to XS, and NIH/NIAID UC6AI058607 to the Duke Biocontainment Laboratory. This work used a high-performance computing facility supported by grants 2016-IDG-1013 and 2020-IIG-2109 from the North Carolina Biotechnology Center.
Funding Information:
MTM reports grants on biomarker diagnostics from the Defense Advanced Research Projects Agency (DARPA), National Institutes of Health (NIH), Sanofi, and the Department of Veterans Affairs. TWB reports grants from DARPA and is a consultant for and holds equity in Predigen and Biomeme. MTM, TWB, ELT, GSG, and CWW report patents pending on Molecular Methods to Diagnose and Treat Respiratory Infections. ELT reports grants on biomarker diagnostics from DARPA, the NIH/Antibacterial Resistance Leadership Group (ARLG); an ownership stake in Predigen and Biomeme; consultancy fees from bioMerieux; GSG reports an ownership stake in Predigen and Biomeme; CWW reports grants on biomarker diagnostics from DARPA, NIH/ARLG, Predigen, and Sanofi; and has received consultancy fees from bioMerieux, Roche, Biofire, Giner, and Biomeme. All other authors NSG, SD, EP, HAC, GOR, EW, RX, SB, TR, BPN, TC, RH, GDS, TND, MIDU, LLS, ERK, BDK and XS have no competing interests to report.
Funding Information:
We thank Eric van Gieson and Thomas Thomou for their advice throughout the project, and Andrew Macintyer, Thomas Oguin, and their teams at the Duke Regional Biocontainment Laboratory for COVID IgG serology and PCR viral load testing. We thank Raul Louzao, Christina Nix, Carolyne Whiting, Tyffany Locklear, Pam Isner, Anna Mazur, Jack Anderson, Maria Miggs, Aleah Bowie, Julie Steinbrink, Robert Rolfe, and Jorge Prado Balcazar for technical expertise. We wish to express our deep appreciation to the participants and their families for their generosity in collaborating with us in this work.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - SARS-CoV-2 infection triggers profound and variable immune responses in human hosts. Chromatin remodeling has been observed in individuals severely ill or convalescing with COVID-19, but chromatin remodeling early in disease prior to anti-spike protein IgG seroconversion has not been defined. We performed the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and RNA-seq on peripheral blood mononuclear cells (PBMCs) from outpatients with mild or moderate symptom severity at different stages of clinical illness. Early in the disease course prior to IgG seroconversion, modifications in chromatin accessibility associated with mild or moderate symptoms were already robust and included severity-associated changes in accessibility of genes in interleukin signaling, regulation of cell differentiation and cell morphology. Furthermore, single-cell analyses revealed evolution of the chromatin accessibility landscape and transcription factor motif accessibility for individual PBMC cell types over time. The most extensive remodeling occurred in CD14+ monocytes, where sub-populations with distinct chromatin accessibility profiles were observed prior to seroconversion. Mild symptom severity was marked by upregulation of classical antiviral pathways, including those regulating IRF1 and IRF7, whereas in moderate disease, these classical antiviral signals diminished, suggesting dysregulated and less effective responses. Together, these observations offer novel insight into the epigenome of early mild SARS-CoV-2 infection and suggest that detection of chromatin remodeling in early disease may offer promise for a new class of diagnostic tools for COVID-19.
AB - SARS-CoV-2 infection triggers profound and variable immune responses in human hosts. Chromatin remodeling has been observed in individuals severely ill or convalescing with COVID-19, but chromatin remodeling early in disease prior to anti-spike protein IgG seroconversion has not been defined. We performed the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) and RNA-seq on peripheral blood mononuclear cells (PBMCs) from outpatients with mild or moderate symptom severity at different stages of clinical illness. Early in the disease course prior to IgG seroconversion, modifications in chromatin accessibility associated with mild or moderate symptoms were already robust and included severity-associated changes in accessibility of genes in interleukin signaling, regulation of cell differentiation and cell morphology. Furthermore, single-cell analyses revealed evolution of the chromatin accessibility landscape and transcription factor motif accessibility for individual PBMC cell types over time. The most extensive remodeling occurred in CD14+ monocytes, where sub-populations with distinct chromatin accessibility profiles were observed prior to seroconversion. Mild symptom severity was marked by upregulation of classical antiviral pathways, including those regulating IRF1 and IRF7, whereas in moderate disease, these classical antiviral signals diminished, suggesting dysregulated and less effective responses. Together, these observations offer novel insight into the epigenome of early mild SARS-CoV-2 infection and suggest that detection of chromatin remodeling in early disease may offer promise for a new class of diagnostic tools for COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85133706591&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-15668-8
DO - 10.1038/s41598-022-15668-8
M3 - Article
C2 - 35810186
AN - SCOPUS:85133706591
VL - 12
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 11714
ER -